Servier Announces FDA Approval of Tibsovo (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
Tibsovo is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia
FDA approval based on data from the global, Phase 3 AGILE trial that...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Drugs & Pharmacology | Leukemia